Abstract
Growth factor signaling via receptor tyrosine kinases plays a central role in initiating and maintaining a malignant phenotype. Fibroblast growth factors (FGF) and their receptor family (FGFR1-4) are key players in various human solid and hematological tumors and have been linked to tumor cell proliferation, resistance to chemotherapy and apoptosis, angiogenesis, invasion and metastasis. FGFRs are commonly activated by genomic alterations or mutations and various approaches to targeted inhibition have been developed. The deeper understanding of the underlying signal transduction mechanisms has generated novel targeted therapy approaches like ligand-traps, receptor-specific antibodies or small molecule kinase inhibitors that are currently undergoing preclinical and clinical development for the treatment of human cancers.
Keywords: Fibroblast growth factor receptor, receptor tyrosine kinase, signal transduction inhibitor, targeted therapy.
Current Signal Transduction Therapy
Title:Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Volume: 9 Issue: 1
Author(s): Melanie Heroult, Peter Ellinghaus, Stuart Ince and Matthias Ocker
Affiliation:
Keywords: Fibroblast growth factor receptor, receptor tyrosine kinase, signal transduction inhibitor, targeted therapy.
Abstract: Growth factor signaling via receptor tyrosine kinases plays a central role in initiating and maintaining a malignant phenotype. Fibroblast growth factors (FGF) and their receptor family (FGFR1-4) are key players in various human solid and hematological tumors and have been linked to tumor cell proliferation, resistance to chemotherapy and apoptosis, angiogenesis, invasion and metastasis. FGFRs are commonly activated by genomic alterations or mutations and various approaches to targeted inhibition have been developed. The deeper understanding of the underlying signal transduction mechanisms has generated novel targeted therapy approaches like ligand-traps, receptor-specific antibodies or small molecule kinase inhibitors that are currently undergoing preclinical and clinical development for the treatment of human cancers.
Export Options
About this article
Cite this article as:
Heroult Melanie, Ellinghaus Peter, Ince Stuart and Ocker Matthias, Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment, Current Signal Transduction Therapy 2014; 9 (1) . https://dx.doi.org/10.2174/157436240901140924103836
DOI https://dx.doi.org/10.2174/157436240901140924103836 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment
Current Diabetes Reviews Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
Current Genomics Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery The First Total Synthesis of Tarennane, a Potent Antioxidant Chalcone Constituent from Tarenna Attenuate or Magnolia Officinalis
Letters in Organic Chemistry The Beneficial Effects of QIAPI 1<sup>®</sup> against Pentavalent Arsenic-Induced Lung Toxicity: A Hypothetical Model for SARS CoV2-I nduced Lung Toxicity
Current Pharmaceutical Biotechnology Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Human Methylome Variation and the Rise of Epigenetic Epidemiology]
Current Pharmacogenomics and Personalized Medicine Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals A Simple and Reliable Approach for Assessing Anticancer Activity In Vitro
Current Medicinal Chemistry Principles of an Adenovirus-Based Assay for Candidate Compounds with Broad Spectrum of Anti-Neoplastic Activities
Letters in Drug Design & Discovery Transplacental Antioxidants Inhibit Lung Tumors in Mice Exposed to Cigarette Smoke After Birth: A Novel Preventative Strategy?
Current Cancer Drug Targets Histone Deacetylase Inhibitors: The Abbott Experience
Current Medicinal Chemistry Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Development of Microwave Antennas for Thermal Therapy
Current Pharmaceutical Design Detection of Melatonin Production from the Intestinal Epithelium Using Electrochemical Methods
Current Pharmaceutical Design The Urokinase Receptor and its Structural Homologue C4.4A in Human Cancer: Expression, Prognosis and Pharmacological Inhibition
Current Medicinal Chemistry The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry